ARTICLE | Company News
Amorfix, Aragen Bioscience deal
June 7, 2010 7:00 AM UTC
Aragen will generate mAbs against disease-specific epitopes on misfolded Fas receptor (CD95) identified by Amorfix to treat cancer. Amorfix will have exclusive, worldwide rights to the mAbs. Further ...